What Has Been The Evolution of the Peanut Allergy Treatment Market in Recent Years?
The peanut allergy treatment market has seen considerable growth due to a variety of factors.
• The peanut allergy treatment market has grown rapidly in recent years. It will rise from $0.45 billion in 2024 to $0.51 billion in 2025, at a compound annual growth rate (CAGR) of 11.4%.
The growth is attributed to the rising prevalence of peanut allergies, advances in diagnostic testing, heightened public awareness, the development of early intervention methods, and regulatory approvals for treatments.
How Will the Peanut Allergy Treatment Market?
The peanut allergy treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The peanut allergy treatment market is expected to grow to $0.77 billion by 2029, with a CAGR of 11.1%.
Growth is driven by the rising prevalence of peanut allergies, the introduction of immunotherapy treatments, increased public and private investments, and telemedicine growth. Trends include the adoption of immunotherapy, biologic therapies, probiotic-based treatments, and personalized medicine.
Which Factors Are Boosting Growth In The Peanut Allergy Treatment Market?
The rise in financial resources dedicated to research and development (R&D) initiatives for allergy therapies is projected to significantly enhance the growth trajectory of the peanut allergy treatment market. These coveted funds, which come from businesses, organizations, or government institutions, are aimed at fostering product innovation, technological progression, and overall market development. The key role of these investments is to facilitate progress in peanut allergy treatments through the establishment of ground-breaking immunotherapies and desensitization methodologies. Such advancements work towards minimizing allergic reactions and elevating the standard of living for individuals grappling with peanut allergies. An illustrative example of such investments is the $12 million funding announced by the Victorian Government in January 2024 for Aravax, an Australian clinical-stage biotech enterprise. This substantial investment, part of a larger $66 million funding round, intends to boost the development of Aravax's pioneering immunotherapy, PVX108, contributing significantly to the global peanut allergy treatment milieu. It is noteworthy that this initiative has already received Phase 2 trial clearances from the prestigious U.S. Food and Drug Administration (FDA) and Australia's Therapeutic Goods Administration (TGA), underlining its potential to influence global public health positively. Consequently, these heavy investments targeted at research and development are fuelling the expansion of the peanut allergy treatment market.
What Key Areas Define The Segmentation Of The Global Peanut Allergy Treatment Market?
The peanut allergy treatment market covered in this report is segmented –
1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes
2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
Subsegments:
1) By Antihistamines: Oral Antihistamines, Topical Antihistamines
2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)
3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers
4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids
Pre-Book The Peanut Allergy Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Peanut Allergy Treatment Market?
Key players in the peanut allergy treatment market are turning their focus towards creating biologic therapies like anti-IgE monoclonal antibodies, intending to provide more precise and effective solutions in managing peanut allergies. This could enhance patient outcomes and their quality of life. Anti-IgE monoclonal antibodies work by targeting and neutralizing immunoglobulin E (IgE) antibodies within the body. In February 2024, for example, an authorization from the Food and Drug Administration (FDA) was received by Novartis Pharmaceuticals Corporation, a Swiss-based pharmaceutical firm, for Xolair (omalizumab). This drug aims to lessen allergic responses, including severe reactions such as anaphylaxis in patients aged 1 and above with IgE-mediated food allergies. The approval originated from data collected from the NIH-sponsored Phase III OUtMATCH study that showed a significant increase in food allergy tolerance in patients treated with Xolair, compared to those given a placebo.
Who Are the Key Players In The Peanut Allergy Treatment Market?
Major companies operating in the peanut allergy treatment market are:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Sanofi SA
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Viatris Inc.
• Regeneron Pharmaceuticals Inc.
• Hikma Pharmaceuticals plc
• ALK-Abelló A/S
• Amneal Pharmaceuticals Inc.
• Amphastar Pharmaceuticals Inc.
• Stallergenes Greer plc
• kaleo Inc.
• Aquestive Therapeutics Inc.
• Vedanta Biosciences Inc.
• Aimmune Therapeutics Inc.
• AnaptysBio Inc.
• Alladapt Immunotherapeutics Inc.
• Aravax Pty Ltd.
• Intrommune Therapeutics Inc.
• IgGenix Inc.
• DBV Technologies SA
• Camallergy Ltd.
• HAL Allergy Group
• Prota Therapeutics Pty Ltd.
What Is The Most Dominant Region In The Peanut Allergy Treatment Market?
North America was the largest region in the peanut allergy treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
